The FDA rejected oral treprostinil, a prostacyclin vasodilator, for the second time for the treatment of pulmonary arterial hypertension. The Agency issued a complete response letter to United Therapeutics explaining the rejection. The drug is on the market in injectable and inhalable forms.

Keywords: Epoprostenol, Vasodilator Agents, Hypertension, Pulmonary

< Back to Listings